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Abstract
Background: Secondary involvement of the thyroid gland is rare. Often the origin of the tumor
is difficult to identify from the material obtained by fine-needle aspiration cytology. Renal cell
carcinoma of the clear-cell type is one of the more common carcinomas to metastasize to the
thyroid gland. Somatic mutations of the von Hippel-Lindau tumor suppressor gene are associated
with the sporadic form of this tumor. We aimed to illustrate the potential utility of DNA based
technologies to search for specific molecular markers in order to establish the anatomic site of
origin.
Case Presentation: A 54-yr-old Caucasian male complaining of a rapidly increasing neck tumor
was diagnosed as having a clear-cell tumor by fine-needle aspiration cytology. A positive staining for
cytokeratin as well as for vimentin and CD10 in the absence of staining for thyroglobulin, calcitonin
and TTF1 suggested a renal origin confirmed by computed tomography.
Using frozen RNA, obtained from cells left inside the needle used for fine needle aspiration
cytology, it was possible to identify a somatic mutation (680 delA) in the VHL gene.
Conclusion: In the presence of a clear-cell tumor of the thyroid gland, screening for somatic
mutations in the VHL gene in material derived from thyroid aspirates might provide additional
information to immunocytochemical studies and therefore plays a contributory role to establish
the final diagnosis. Moreover, in a near future, this piece of information might be useful to define a
targeted therapy.
Background
Metastasis to the thyroid is an uncommon occurrence. In
clinical series, the frequency of secondary involvement of
the thyroid is considerably lower than the frequency of
25% found at autopsy of patients with disseminated
malignancies [1,2].
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The increasing number of reported cases of secondary
tumors to the thyroid, as suggested by two studies from
the Mayo Clinic referring to distinct periods [1,3], is prob-
ably related with routine evaluation of thyroid nodules in
patients with known cancer by fine-needle aspiration
cytology (FNAC) [4]. Nonetheless, the diagnosis of sec-
ondary involvement of the thyroid gland in a patient with
an asymptomatic primitive neoplasm is still challenging.
Secondary involvement of the thyroid gland by renal cell
carcinoma (RCC) clear-cell type (CCRCC) is rare; however
CCRCC is one of the more common neoplasms to metas-
tasize to the thyroid gland [5]. Since metastatic clear-cell
RCC must be distinguished from a variety of neoplasms
with clear-cell features including primitive tumors of thy-
roid, interpretation of FNAC may be a diagnostic problem
for the pathologist [6,7] and imposes the combination of
routine immunohistochemical studies. A different
approach might be the use of DNA based technologies.
Screening for molecular markers or somatic mutations
known to be specific of particular tumors appears as a
promising tool to refine diagnosis. In this setting, consid-
ering that the von Hippel-Lindau tumor suppressor gene
(VHL) is mutated or silenced in more than 50% of spo-
radic renal cell carcinomas of the clear cell type [8-12],
identification of a mutation in the VHL  gene in DNA
derived from the leftover cells in the needle used for FNAC
might be helpful to establish the origin of the primitive
tumor.
Case presentation
Case history
A 54-yr-old Caucasian male was referred for evaluation of
a rapidly increasing neck tumor noticed for the first time
four months earlier. He complained of sporadic dys-
phagia without weight loss. He was a heavy smoker until
recently but had no previous medical history. He worked
as a house painter, for seven years, in his thirties. The
physical examination revealed an asymmetric multinodu-
lar goiter with a left dominant nodule with firm consist-
ency and no palpable regional nodes. Serum TSH was 1.3
μUI/ml (normal: 0.5–4.7 μUI/ml), T4 7.3 μg/dl (normal:
5.4–11 μg/dl) and T3 126 ng/dl (normal: 52–160 ng/dl).
Antimicrosomal and antithyroglobulin antibodies were
negative. A thyroid ultrasound demonstrated a multinod-
ular gland with the right and left lobes measuring 6 × 4 ×
3 cm and 9 × 7 × 6 cm respectively. A computed tomogra-
phy (CT) scan of the neck showed a slight tracheal devia-
tion to the right without compression. A Tc-99 m
scintigraphy disclosed irregular uptake in both lobes of
the thyroid and a large cold nodule in the left lobe. FNAC
from both lobes revealed a clear-cell carcinoma with an
immunocytochemical profile suggestive of a secondary
tumor from the kidney (refer to section pathology).
FNAC results prompted a clinical and radiographic inves-
tigation. An abdominal CT scan revealed a tumor of the
left kidney measuring in greatest diameter 10 cm. Bone
scan, chest computed tomography scan, liver ultrasound
and laboratory data were normal and there was no evi-
dence of other distant metastases.
Initial treatment included a left radical nephrectomy and
a total thyroidectomy. One year later, there was evidence
for cervical nodal metastases. The patient was then sub-
mitted to right radical neck dissection with internal jugu-
lar vein ligation and section of spinal accessory nerve and
left modified radical neck dissection type III. At histologi-
cal examination, only right nodes were metastatic.
Pathology
Both thyroid lobes were sampled. Smears were air dried
and acetone fixed and stained with May-Grünwald-
Giemsa (MGG) and Papanicolaou (PAP) stains, respec-
tively. An additional sample was fixed in formalin and
processed as a cell-block using the Shandon Cytoblock®
Kit (Thermo Electron Corporation, Pittsburgh, PA, USA).
Cell block (CB) sections were stained with hematoxilin-
eosin. Immunocytochemistry was performed on CB sec-
tions, using an avidin-biotin method with diaminobenzi-
dine as the chromogen for the following antibodies:
thyroglobulin, calcitonin, vimentin, CD10, TTF1 (Dako-
cytomation, Denmark A/S) and cytokeratin AE1/AE3
(Zymed Laboratories, Inc, San Francisco, CA).
Smears consisted of a clear, large cell neoplasia with large
nuclei, prominent nucleoli and finely vacuolated cyto-
plasm, with indistinct borders. The tumor cells were
arranged in aggregates of variable size and shape, many of
them centered by thin walled capillaries. This intimate
relationship of neoplastic cells and vessels was better
appreciated on cell-block sections. These cells were immu-
noreactive for pancytokeratin (AE1/AE3), vimentin and
CD10 and were negative for thyroglobulin, thyroid tran-
scription factor1 (TTF1) and calcitonin (Fig. 1).
The smear pattern together with the immunocytochemi-
cal profile was consistent with the diagnosis of secondary
tumor, most probably from renal origin.
The nephrectomy specimen showed a renal cell carci-
noma, clear cell type. It was classified as Fuhrman 3 and
showed extra renal local spread and no vascular invasion.
The thyroid gland was multinodular and all the nodules
consisted of metastasis of a clear cell neoplasia. The histo-
logical pattern was similar to the renal tumor. Immunocy-
tochemical study was performed using the same
antibodies that were tested on cytological samples with
identical results.BMC Endocrine Disorders 2006, 6:6 http://www.biomedcentral.com/1472-6823/6/6
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VHL mutation analysis
RNA from cells left inside of the needle used for FNAC was
isolated with the QuickPrep micro mRNA Purification Kit
(Amersham Pharmacia Biotech, Buckinghamshire, UK),
according to the manufacturer's instructions. Half of the
RNA was reversed transcribed with Superscript (Invitro-
gen Corporation, Carlsbad, CA, USA) in 20 μl reaction
volume with random primers and cDNA kept frozen. To
screen for VHL mutations in thyroid aspirates, 2,5 μl of
first-strand cDNA was used as a template for PCR using
primers designed by us (F-5'-TCAGAGATGCAG-
GGACACAC-3', R-5'-TGACGATGTCCAGTCTCCTG-3').
Somatic DNA was extracted from samples corresponding
to renal carcinoma and thyroid metastases obtained dur-
ing surgeries and immediately frozen with liquid nitrogen
until nucleic acid extraction using TRIzol Reagent (Life
Technologies, Inc., Gaithersburg, MD, USA). Genomic
DNA was also obtained from peripheral venous blood
and isolated by a manual method adapted from Bowtell
[13].
DNA samples were amplified by PCR using primers previ-
ously described [14]. The screening of VHL mutations was
performed by single-strand conformational polymor-
phism analysis (SSCP). To further characterize the abnor-
A – Tumor cells with clear cytoplasm, large atypical nuclei, conspicuous nucleoli (A1 – MGG; ×400; A2 – PAP; ×400) Figure 1
A – Tumor cells with clear cytoplasm, large atypical nuclei, conspicuous nucleoli (A1 – MGG; ×400; A2 – PAP; ×400). B – Cell-
block section. Prominent vascular pattern (H&E; ×100). C – Cell block. Immunoreactivity for AE1/AE3 (×400). D – Cell block. 
Immunoreactivity for vimentin (×400). E – Cell block. Negative immunostain for TTF1 (×400). F – Cell block. Strong surface 
membrane staining for CD10 (×400).
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mal pattern observed in the SSCP, PCR purified products
were either sequenced directly using the ABI PRISM®
BigDye™ Terminator Cycle Sequencing Ready Reaction Kit
(Applied Biosystems, Foster City, CA, USA) and the ABI
PRISM 310 Genetic Analyser or subcloned into pGEM®-T
Easy Vector (Promega, Madison, USA), and subsequently
sequenced using the ABI PRISM®  BigDye™ Terminator
Cycle Sequencing Ready Reaction Kit (Applied Biosys-
tems, Foster City, CA, USA) and the ABI PRISM 310
Genetic Analyser. Restriction analysis, using the restric-
tion endonuclease BstZ17 I (New England BioLabs®, Inc.,
Beverly, USA) was also performed.
The same alteration, a heterozygous 680delA (codon 156/
exon 3) of the VHL gene was identified in thyroid aspi-
rates, renal carcinoma, thyroid metastases and lymph
node metastases. It causes a frame-shift and creates a pre-
mature stop predicting a truncated pVHL (Fig. 2). Consti-
tutional DNA (peripheral venous blood) was analyzed
and did not show the mutation. No other alterations were
observed in exons 1 and 2 of VHL.
Conclusion
Metastatic disease to the thyroid gland from distant sites
is rare. Breast and lung carcinoma are the most frequently
identified sources of secondary thyroid carcinoma found
at autopsy while renal cell carcinoma comprises over 50%
of secondary thyroid malignancies discovered clinically
[15]. Clear-cell RCC is the most common malignant neo-
plasm of the kidney [16]. Although the kidney is the most
common primary anatomic site for clear-cell tumor, other
primary sites include the lung, salivary gland, breast,
ovary, endometrium, cervix, vagina, pancreas, liver, adre-
nal gland and thyroid [6].
Metastases of a clear-cell tumor present similar morpho-
logic features regardless the origin of the primitive tumor.
In a patient with a past history of malignancy elsewhere,
the finding of a clear-cell tumor on thyroid aspirates will
prompt the hypothesis of a secondary tumor. The sudden
enlargement of the thyroid in an otherwise healthy individ-
ual, as it was the case in our patient, makes the diagnosis of
metastatic disease challenging for the cytopathologist and
reinforces the need of immunohistochemical studies [6,7].
A positive staining for cytokeratin as well as for vimentin
and CD10 in the absence of staining for thyroglobulin, cal-
citonin and TTF1, observed in smears from both lobes of
the thyroid, favored the hypothesis of metastasis from a
renal carcinoma. These findings guided the subsequent
diagnostic workup and a hitherto occult neoplasm of the
left kidney was documented. Curiously, from literature, the
left kidney seems to be more affected [5].
RCC is a highly treatment-resistant tumor type and sur-
gery remains the standard approach. Pending the extent of
the metastatic disease and the general condition of the
patient, the surgical management of metastases is justified
as long term survivals have been reported [17-19]. Con-
sidering the solitary nature of thyroid metastases in our
patient, after a radical nephrectomy a total thyroidectomy
was performed.
Since somatic VHL mutations account for the majority of
sporadic CCRCCs [8,12] and may represent a prognostic
factor [12] we sought for mutations of the VHL gene in
different samples of tumor DNA including frozen cDNA
obtained from the cells left inside the needle used for fine-
needle aspiration cytology. cDNA had been obtained and
kept frozen in the setting of an independent ongoing
study to seek for molecular markers in thyroid aspirates.
The same heterozygous mutation, a 680 delA, (codon 156/
exon 3), was observed in all tumor samples and absent in
constitutional DNA. The tumor was therefore defined as
sporadic. Although a broad spectrum of somatic VHL
mutations has been described in patients with CCRCCs,
mutations cluster within exon 2 [8]. To the best of our
knowledge, the mutation we identified in the present case
was not previously reported [8,9,11,12,20,21]. Non-ran-
dom distribution of somatic VHL mutations may originate
from exposure to exogenous carcinogens [22]. According
to the 2-hit theory of tumor suppressor genes, another hit
in VHL might be involved. Hypermethylation studies were
not conducted thus we can not exclude inactivation of the
wild type allele and on the other hand, contamination
with normal tissue can not be ruled out. Despite the previ-
ous comment, the frequency of biallelic inactivation of
VHL in sporadic renal cell carcinomas was found to be
unexpectedly low [23].
The possibility to screen for VHL mutations in thyroid
aspirates may help in distinguishing metastatic renal cell
carcinoma from other primary clear-cell tumors. VHL
mutations have not been identified in the thyroid except
in MEN 2 associated medullary thyroid carcinoma [24]
although LOH in the VHL gene has been identified in fol-
licular carcinomas of the thyroid [25]. Herein, we used
frozen cDNA obtained from cells left inside the needle
used for FNAC. Contamination by normal thyroid cells,
as verified by thyroglobulin expression (data not shown),
did not blur the results.
The VHL gene regulates the oxygen-dependent expression
of genes involved in the cellular response to oxygen dep-
rivation.  VHL  interacting with the transcription factors
hypoxia inducible factors HIF 1α and HIF 2α mediates
transcriptional activation of genes involved in angiogen-
esis, erythropoesis and anaerobic metabolism. Given that
multiple pathways contribute to tumor growth, it is con-BMC Endocrine Disorders 2006, 6:6 http://www.biomedcentral.com/1472-6823/6/6
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ceivable that anti-tumor activity may be increased by
agents targeting multiple pathways [26-28].
Thus, identification of a somatic mutation in the VHL
gene may be helpful to establish a diagnosis as well as to
make a decision concerning emerging targeted therapies
[29].
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